Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.

Open access
Rodbard, Helena W, Lingvay, Ildiko, Reed, John, de la Rosa, Raymond, Rose, Ludger, Sugimoto, Danny, Araki, Eiichi, Chu, Pei-Ling, Wijayasinghe, Nelun, Norwood, Paul · 2018 · The Journal of Clinical Endocrinology & Metabolism

Abstract

Context: Combination therapy with insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is important for treating type 2 diabetes (T2D). This trial assesses the efficacy and safety of semaglutide, a GLP-1RA, as an add-on to basal insulin. Objective: To demonstrate the superiority of semaglutide vs placebo on glycemic control as an add-on to basal insulin in patients with T2D. Design: Phase 3a, double-blind, placebo-controlled, 30-week trial. Setting: This study included 90 sites in five countries. Patients: We studied 397 patients with uncontrolled T2D receiving stable therapy with basal insulin with or without metformin. Interventions: Subcutaneous semaglutide 0.5 or 1.0 mg once weekly or volume-matched placebo. Main Outcome Measures: Primary endpoint was change in glycated Hb (HbA1c) from baseline to week 30. Confirmatory secondary endpoint was change in body weight from baseline to week 30. Results: At week 30, mean HbA1c reductions [mean baseline value, 8.4% (67.9 mmol/mol)] with semaglutide 0.5 and 1.0 mg were 1.4% (15.8 mmol/mol) and 1.8% (20.2 mmol/mol) vs 0.1% (1.0 mmol/mol) with placebo [estimated treatment difference (ETD) vs placebo, -1.35 (14.8 mmol/mol); 95% CI, -1.61 to -1.10 and ETD, -1.75% (19.2 mmol/mol); 95% CI, -2.01 to -1.50; both P < 0.0001]. Severe or blood glucose-confirmed hypoglycemic episodes were reported in 11 patients (17 events) and 14 patients (25 events) with semaglutide 0.5 and 1.0 mg, respectively, vs seven patients (13 events) with placebo (estimated rate ratio vs placebo, 2.08; 95% CI, 0.67 to 6.51 and estimated rate ratio vs placebo, 2.41; 95% CI, 0.84 to 6.96 for 0.5 and 1.0 mg; both P = nonsignificant). Mean body weight decreased with semaglutide 0.5 and 1.0 mg vs placebo from baseline to end of treatment: 3.7, 6.4, and 1.4 kg (ETD, -2.31; 95% CI, -3.33 to -1.29 and ETD, -5.06; 95% CI, -6.08 to -4.04 kg; both P < 0.0001). Premature treatment discontinuation due to adverse events was higher for semaglutide 0.5 and 1.0 mg vs placebo (4.5%, 6.1%, and 0.8%), mainly due to gastrointestinal disorders. Conclusions: Semaglutide, added to basal insulin, significantly reduced HbA1c and body weight in patients with uncontrolled T2D vs placebo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2018-00070

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Change in (A) mean HbA1c, (B) fasting plasma glucose, (C) body weight, and (D) time to onset of hypoglycemia over time. Values are estimated means ± standard error from a mixed model for repeated measurements analysis using “on-treatment without rescue medication” data from patients in the full analysis set. The dashed line indicates the overall mean value at baseline. Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. bSignificant at P ≤ 0.0002. ETD, estimated treatment difference.
Figure 1. Change in (A) mean HbA1c, (B) fasting plasma glucose, (C) body weight, and (D) time to onset of hypoglycemia over time. Values are estimated means ± standard error from a mixed model for repeated measurements analysis using “on-treatment without rescue medication” data from patients in the full analysis set. The dashed line indicates the overall mean value at baseline. Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. bSignificant at P ≤ 0.0002. ETD, estimated treatment difference.CC BY · PubMed Central
Figure 2. Patients achieving (A) an HbA1c target of <7% and (B) a body weight loss target of ≥5% (American Association of Clinical Endocrinologists target) at week 30. Values are observed proportions using “on-treatment without rescue medication” data from patients in the full analysis set. Missing HbA1c and body weight data are imputed from a mixed model for repeated measurements analysis and subsequently classified. Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. EOR, estimated OR.
Figure 2. Patients achieving (A) an HbA1c target of <7% and (B) a body weight loss target of ≥5% (American Association of Clinical Endocrinologists target) at week 30. Values are observed proportions using “on-treatment without rescue medication” data from patients in the full analysis set. Missing HbA1c and body weight data are imputed from a mixed model for repeated measurements analysis and subsequently classified. Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. EOR, estimated OR.CC BY · PubMed Central
Figure 3. Patients achieving the composite endpoint target of HbA1c <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemia and with no weight gain. Values are observed proportions using “on-treatment without rescue medication” data from patients in the full analysis set. Missing HbA1c and body weight data were imputed from a mixed model for repeated measurements analysis and subsequently classified. “Blood glucose-confirmed” defined as blood glucose <3.1 mmol/L (56 mg/dL). Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. EOR, estimated OR.
Figure 3. Patients achieving the composite endpoint target of HbA1c <7.0% without severe or blood glucose–confirmed symptomatic hypoglycemia and with no weight gain. Values are observed proportions using “on-treatment without rescue medication” data from patients in the full analysis set. Missing HbA1c and body weight data were imputed from a mixed model for repeated measurements analysis and subsequently classified. “Blood glucose-confirmed” defined as blood glucose <3.1 mmol/L (56 mg/dL). Values in square brackets indicate 95% CIs. aSignificant at P < 0.0001. EOR, estimated OR.CC BY · PubMed Central
Figure 4. Observed mean seven-point self-measured blood glucose profile at baseline and at week 30. Values are observed means based on “on-treatment without rescue medication” data from patients in the full analysis set. Dashed lines represent week 0 data; solid lines represent week 30 data.
Figure 4. Observed mean seven-point self-measured blood glucose profile at baseline and at week 30. Values are observed means based on “on-treatment without rescue medication” data from patients in the full analysis set. Dashed lines represent week 0 data; solid lines represent week 30 data.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Research works printed but not linked: 1

  1. Marbury, 2014, Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP-1 analogue, in subjects with and without renal impairment, Diabetologia, 57, S358

Cited by

See all 412

Metadata

Authors
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P.
Affiliations
  • Endocrine and Metabolic Consultants, Rockville, Maryland
  • The University of Texas Southwestern Medical Center (US)
  • Endocrine Research Solutions (United States) (US)
  • Four Rivers Clinical Research, Paducah, Kentucky
  • Institute of Diabetes Research, Münster, Germany
  • Cedar-Crosse Research Center, Chicago, Illinois
  • Kumamoto University (JP)
  • Novo Nordisk Inc., Plainsboro, New Jersey
  • Novo Nordisk (Denmark) (DK)
  • University of California, San Francisco (US)
Corresponding author
Rodbard, Helena W
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2018-04-23
Volume
103
Issue
6
Pages
2291-2301
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2801715295
Cited by
412
References
43
Citations by year
2026: 50 · 2025: 63 · 2024: 69 · 2023: 44 · 2022: 57 · 2021: 40 · 2020: 46 · 2019: 31 · 2018: 10
FWCI
25.27
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Novo Nordisk
  • Japan Society for the Promotion of Science (17H04201, 18K08482)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
semaglutide, basal insulin, type 2 diabetes, GLP-1 receptor agonists, adjunctive therapy, glycemic control, HbA1c, body weight, hypoglycemia, drug safety, metformin, weight loss, insulin dose reduction, HbA1c reduction, adverse events, drug discontinuation
MeSH terms
Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Middle Aged, Treatment Outcome, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. https://app.cochat.ai/papers/10.1210/jc.2018-00070
The paper
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018). Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2018-00070

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.